You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Diffused Optical Tomography using Oxygen-sensitive Luminescent Contrast Agent for

    SBC: RADIATION MONITORING DEVICES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Molecule specific targeting and improving image contrast have been recognized as important research areas in cancer imaging. Goal of cancer diagnosis and prognosis research is to develop new imaging techniques to detect lesions with certainty in early stages so that they can be treated. Developing biomarkers, which will signal the presence and the type of lesio ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting alpha particle-emitting radionuclides to the nuclei of cancer cells

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): This proposal outlines a body of research to evaluate the cytotoxicity and therapeutic efficacy of radiolabeled alpha-melanocyte stimulating hormone (a-MSH) peptide analogs that target a-particle emitting radioisotopes to the nuclei of melanoma cells. The selective targeting of alpha-particle emitting radioisotopes for cancer therapy is emerging as an exciting ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  3. Processing Ac-227 sources for lead-212 and radium-223 required by cancer research

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): NIH sponsored cancer researchers have been obtaining promising results using molecules radiolabeled with lead-212 in treatment for metastatic melanoma and disseminated colon and pancreatic cancers. Another isotope, radium-223 is being used in clinical trials in treatment of skeletal metastases. There is no effective therapy for these diseases. Together 199,280 ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  4. Alkylating Vitamin D Derivative

    SBC: APHIOS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Prostate cancer is the most prevalent cancer among men; and the second leading cause of cancer death among men in the US. There are currently no approved therapies for hormone-refractory prostate cancer. Epidemiological studies have demonstrated a strong relationship between incidence of and mortality from various cancers including prostate cancer, exposure to ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  5. An Interactive Informed Consent Program for Cardiac Procedures

    SBC: ARCHIE MD INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Informed consent has become an essential component of the doctor-patient interaction. The informed consent process requires that patients not only be given information about proposed medical treatment, but that it be presented in an understandable way so the patient can make meaningful choices about medical alternatives. At the heart of the inf ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  6. CAN CD 133 CELLS PREVENT HYPOXIA DRIVEN RETINAL NEOVASCULARISATION IN A RODENT MO

    SBC: Arteriocyte, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The clinical significance of ocular angiogenesis is enormous, due to the fact that in the western hemisphere, retinal neovascularization resulting from diabetic retinopathy is the most common cause of new blindness in young patients, and choroidal neovascularization (CNV) resulting from AMD is the chief cause of severe and irreversible loss of vision in elderly ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  7. Long distance nerve regeneration via processed allografts in a caprine model

    SBC: Axogen Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Every year in the US, several million people suffer serious peripheral nerve injury. Injuries to the peripheral nervous system (PNS) are a major source of disability, impairing the ability to move muscles or to feel normal sensations. To treat these problems, more than one million procedures were performed in the US in 2002, totaling more than $10 billion in me ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  8. User Adaptation of AAC Device Voices

    SBC: BIOSPEECH INC            Topic: N/A

    DESCRIPTION (provided by applicant): A wide range of individuals cannot communicate by voice. Voice enabled Augmentative and Alternative Communication (AAC) devices are often the only channel available by which these individuals can communicate. While many voice enabled AAC devices are currently available, they lack the important ability to generate customized speech that mimics aspects of the use ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  9. HUCBC modulation of Alzheimer-like pathology and behavioral changes

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Modulation of the inflammatory cascade by several diverse strategies including A immunization, non-steroidal anti-inflammatory drug (NSAID) administration, and manipulation of microglial activation states have all been shown to reduce Alzheimer disease (AD)-like pathology, and cognitive deficits in AD transgenic mouse models. Our recent study demonstrated ameli ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Designed Antimalarial Agents Overcoming Chloroquine-Resistance

    SBC: DESIGNMEDIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The intent of the work presented in this proposal is to counter the worldwide health problem brought on by the spread of chloroquine-resistant malaria. To address the need for an orally available and inexpensive replacement drug, we have developed a novel class of molecules called "reversed chloroquines" (RCQs) which act against both chloroquine-resistant and c ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government